Neuropore

News

Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

See All News

Events

Neuropore Therapies (NPT^®) Presents at the 2018 Advances in Alzheimer's and Parkinson's Therapies ‐ an AAT ‐ AD/PD Focus Meeting in Torino, Italy March 15th, 2018 The poster presentation entitled, "Beneficial effects of NPT520-34 in multiple models of neurodegenerative disorders", will be presented by Dr. Diana L. Price.

Click here for more information

See All Events

NPT^® Publications

Neuropore publishes paper describing the discovery and characterization of a small molecule compound targeting α-synuclein as a potential Parkinson’s disease therapeutic October 5th, 2016

Report in Brain, describes findings supporting the hypothesis that NPT^®100-18A reduces alpha-synuclein toxicity through a novel mechanism that involves displacing pathological alpha-synuclein from the membrane.

See All Publications